HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2007.120691v1 93/4/F257    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Farombi-Oghuvbu, I Articles by Corcoran, J D PubMed PubMed Citation Articles by Farombi-Oghuvbu, I Articles by Corcoran, J D Topic Collections Relevant Article

N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus

¹ Department of Neonatal Paediatrics, Rotunda Hospital, Dublin, Ireland
² Department of Clinical Biochemistry, Rotunda Hospital, Dublin, Ireland

Correspondence to:
Dr I Farombi-Oghuvbu, Department of Neonatal Paediatrics, Rotunda Hospital, Parnell Street, Dublin 1, Ireland; ibuky{at}hotmail.com

Background: B-type natriuretic peptide (BNP) is a marker for ventricular dysfunction secreted as a pre-prohormone, pro-B-type natriuretic peptide (proBNP), and cleaved into BNP and a biologically inactive fragment, N-terminal pro-B-type natriuretic peptide (NT-proBNP). Little is known about the clinical usefulness of NT-proBNP in preterm infants.

Objective: To evaluate the usefulness of plasma NT-proBNP in diagnosing haemodynamically significant patent ductus arteriosus (hsPDA) in neonates and examine some factors that might affect this.

Methods: Infants born at <34 weeks’ gestational age (GA) and <2 kg birth weight (BW) were prospectively enrolled within 6–12 hours of birth. Plasma NT-proBNP levels were measured on days 1, 3, 5 and 10 with simultaneous echocardiography done to detect hsPDA and assess ventricular function. Significant PDA was diagnosed by large ductal flow with left to right shunt on colour Doppler, measuring >1.6 mm on two-dimensional echocardiography, along with clinical features of PDA.

Results: Forty-nine infants were analysed. Median GA was 30 weeks (range 24–33) and median BW 1220 g (range 550–1950). Eighteen infants with hsPDA had higher day 3 plasma NT-proBNP values (median 32 907 pg/ml; range 11 396–127 155) (p<0.001) than controls (median 3147 pg/ml; range 521–10 343). Infants who developed sepsis had higher day 10 plasma NT-proBNP levels. Area under receiver operator characteristic curve for detection of hsPDA, by day 3 NT-proBNP value, was significant 0.978 (95% CI 0.930 to 1.026). NT-proBNP was predictive of hsPDA (sensitivity 100%; specificity 95%) at a cut-off value of 11 395 pg/ml.

Conclusion: Plasma NT-proBNP level on day 3 is a good marker for hsPDA in preterm infants. Serial measurements of NT-proBNP may be useful in assessing the clinical course of PDA.

This article has been cited by other articles:

				J. Gien Controversies in the Management of Patent Ductus Arteriosus NeoReviews, October 1, 2008; 9(10): e477 - e482. [Abstract] [Full Text] [PDF]